OakChart

C4 Therapeutics Inc

CCCCHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 10:58 AM ET

3.03+0.03 (1.07%)
2026-11-11 16:58 CET
Market cap
393.95 USD m
Revenue, TTM
32.28 USD m
Net income, TTM
-91.09 USD m
Free cash flow, TTM
-79.74 USD m
EPS diluted, TTM
-0.72
P/E
-
Compare

Price

CCCC against its 20, 50 and 200-day averages
2050200beat
3.004.005.0010.1M20.1MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CCCCclose 3.0320-day 3.1050-day 3.18200-day 3.243.0352w high

41.4% under the 52-week high of 5.17 on 30 Jun 2026. 52-week low 1.69 on 5 Feb 2026. Last 15 sessions, 21.5% high to low

Profile

CCCC
52-week range, 39% of the way up
1.695.17

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in 2015 and is headquartered in Watertown, MA.

IndexRUT
Employees104
IPOOct 02, 2020
Beta3.17
ATR, 14d0.22
Rel volume0.52
Short float38.58%
Insider own8.05%
Inst own92.32%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap398.15M
Enterprise Value248.00M
Income-91.09M
Sales32.28M
Book/sh1.74
Cash/sh1.56
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees104
IPOOct 02, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S12.33
P/B1.74
P/C1.94
P/FCF-
EV/EBITDA-
EV/Sales7.68
Quick Ratio5.17
Current Ratio5.17
Debt/Eq0.24
LT Debt/Eq0.21
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.72
EPS next Y-0.85
EPS next Q-0.23
EPS this Y39.20%
EPS next Y-9.73%
EPS next 5Y7.46%
EPS past 3/5Y21.55% 3.84%
Sales past 3/5Y4.95% 1.61%
EPS Y/Y TTM57.15%
Sales Y/Y TTM7.20%
EPS Q/Q63.79%
Sales Q/Q-24.59%
EarningsNov 05 BMO
EPS/Sales Surpr.17.74% -0.58%

Ownership

Insider Own8.05%
Insider Trans0.00%
Inst Own92.32%
Inst Trans25.65%
ROA-30.50%
ROE-47.62%
ROIC-32.94%
Gross Margin77.74%
Oper. Margin-315.86%
Profit Margin-282.22%
SMA20-2.24%
SMA50-4.57%
SMA200-6.56%
Trades-

Technical

Shs Outstand131.31M
Shs Float120.75M
Short Float38.58%
Short Ratio18.63
Short Interest46.58M
52W High5.17 -41.35%
52W Low1.69 79.40%
Volatility9.13% 7.66%
ATR (14)0.22
RSI (14)46.77
Beta3.17
Rel Volume0.52
Avg Volume2.50M
Volume345,860

Performance

Perf Week-2.82%
Perf Month9.06%
Perf Quarter-25.69%
Perf Half Y-17.61%
Perf YTD58.74%
Perf Year22.26%
Perf 3Y76.28%
Perf 5Y-92.94%
Perf 10Y-
Recom1.11
Target Price12.50
Prev Close3.00
Price3.03
Change %1.07%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 28, 2026InitiatedLLake StreetBuy$11+262.8%
Oct 09, 2026InitiatedJJP MorganOverweight$10+229.8%
Dec 02, 2025InitiatedTTD CowenBuy
Sep 17, 2025InitiatedBBarclaysOverweight$8+163.9%
Sep 15, 2025UpgradeSStephensEqual-Weight → Overweight$6+97.9%
Sep 04, 2025InitiatedGGuggenheimBuy$8+163.9%
Dec 19, 2024UpgradeWWells FargoEqual Weight → Overweight$8 → $12+295.8%
Nov 18, 2024InitiatedSStephensEqual-Weight$4+31.9%
Jan 29, 2024UpgradeJJP MorganUnderweight → Neutral$6+97.9%
Dec 13, 2023UpgradeSStifelHold → Buy$2 → $12+295.8%

Peers

Mkt cap
TickerCompanyMkt cap
ARVNArvinas Inc444.20M
NRIXNurix Therapeutics Inc1.79B
GLUEMonte Rosa Therapeutics Inc880.99M
KYMRKymera Therapeutics Inc11.54B
IMRXImmuneering Corp251.31M
ZNTLZentalis Pharmaceuticals Inc191.13M
IDYAIdeaya Biosciences Inc3.14B
BMYBristol-Myers Squibb Co125.69B
RCUSArcus Biosciences Inc2.70B
TNGXTango Therapeutics Inc4.28B

Insider trading

8 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Mark MosslerOfficerAug 14 '26Proposed Sale4.254,13917,605Aug 14 07:14 PM
JAY GELDMACHERFormer REZI CEOAug 14 '26Proposed Sale23.0182,5631,899,926Aug 14 06:56 PM
Mark MosslerOfficerAug 13 '26Proposed Sale4.0715,00061,072Aug 13 04:18 PM
Mark MosslerOfficerAug 12 '26Proposed Sale3.9319,51976,680Aug 12 05:31 PM
Anderson Kenneth CarlDirectorJun 01 '26Option Exercise2.111,0702,25869,300Jun 04 04:14 PM
Mark MosslerFormer Section 16 OfficerMay 27 '26Proposed Sale3.919,08735,485May 28 08:31 PM
JOLIE M SIEGELOfficerMar 09 '26Proposed Sale3.74101,175378,849Mar 09 04:20 PM
REYNO LEONARDChief Medical OfficerJan 16 '26Sale2.2210,00022,200156,382Jan 16 04:27 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
DFASU.S. Small Cap Portfolio-ETF Class Shares-
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 206
  • C4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire) -5.45%
  • C4 Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
  • C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders (GlobeNewswire)
  • Insmed Appoints Two New Directors to Its Board (PR Newswire) +9.34%
  • Loading…
  • C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting (GlobeNewswire)
  • C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting (GlobeNewswire)
  • C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire) +6.91%
  • C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population (GlobeNewswire)
  • C4 Therapeutics to Participate in Upcoming Conferences (GlobeNewswire) +5.47%
  • C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.55%
  • C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.160-0.195-0.1608.478.528
2026Q22026-08-11-0.180-0.226-0.1816.644.005
2026Q12026-05-12-0.200-0.251-0.1996.204.427
2025Q42026-02-26-0.180-0.288-0.17511.025.397
2025Q32025-11-06-0.440-0.406-0.44311.206.287
2025Q22025-08-07-0.370-0.384-0.3666.466.555
2025Q12025-05-07-0.370-0.442-0.3727.204.457
2024Q42025-02-27-0.490-0.493-0.4905.185.098
2024Q32024-10-31-0.350-0.379-0.35415.405.907
2024Q22024-08-01-0.260-0.364-0.25812.014.787
2024Q12024-05-08-0.410-0.365-0.4143.0411.998
2023Q42024-02-22-0.680-0.687-0.6793.273.2010
2023Q32023-11-01-0.550-0.663-0.54911.075.2810
2023Q22023-08-08-0.730-0.684-0.7322.666.4110
2023Q12023-05-04-0.710-0.747-0.7093.765.468
2022Q42023-02-23-0.760-0.744-0.7592.859.878

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-5.830-7.943-1.54133.2032.92
2021FY-1.820-2.050-1.82245.7933.08
2022FY-2.620-2.593-2.62331.1039.80
2023FY-2.670-2.604-2.66920.7621.45
2024FY-1.520-1.491-1.51835.5835.79
2025FY-1.270-1.406-1.20535.9530.36
2026FY--0.772--29.09
2027FY--0.847--23.51
2028FY--1.006--20.46
2029FY-0.728--779.7
2030FY-5.170--2,619

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-057215.520.008.70
2026Q4S2026-10-277004.930.008.00
2026Q4S2026-10-256004.670.008.00
2026Q4S2026-10-086124.670.008.00
2026Q4S2026-09-245124.000.007.80
2026Q4S2026-08-275124.000.007.80
2026Q4S2026-08-114123.750.007.80
2026Q4S2026-08-074104.290.009.30
2026Q4S2026-07-265104.430.009.30
2026Q4S2026-06-225214.430.009.30
2026Q4S2026-06-105224.430.009.30
2026Q4S2026-06-095134.420.009.30
2026Q4S2026-05-126134.520.009.30
2026Q4S2026-04-086114.700.008.20

Estimate history

EPS, annual-0.573-0.99-1.541-1.822-2.623-2.669-1.518-1.267-0.7161
Period20182019202020212022202320242025TTM
EPS, quarterly-0.354-0.49-0.372-0.366-0.443-0.175-0.199-0.181-0.161
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual19.36421.38133.19545.78531.09620.75635.58435.94732.28
Period20182019202020212022202320242025TTM
Sales, quarterly15.3625.1777.2386.46311.2311.0166.1526.6418.468
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual42.09342.98543.0648.68948.96660.46770.62696.914131.309
Period20182019202020212022202320242025MRQ
Shares, quarterly70.56370.62670.9971.00774.17596.914104.036122.906131.309
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue32.2835.9535.5820.7631.1045.7833.2021.3819.36
Cost of Goods Sold Incl. D&A7.187.977.897.747.572.91---
Gross Profit25.0927.9727.6913.0223.5242.88---
Selling, General and Administrative Excl. Other127.04132.46144.87152.05153.06125.0190.8054.0932.18
Research and Development98.86104.24110.64117.71117.8494.6776.8246.5627.39
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-101.95-104.49-117.18-139.03-129.53-82.13-60.45-35.45-16.39
Interest Expense0.000.000.001.372.222.151.230.000.00
Unusual Expense0.0010.732.440.620.000.005.680.000.00
Net Income Before Taxes-90.97-104.87-105.19-131.21-128.18-83.89-66.96-33.30-15.71
Income Taxes0.120.120.131.280.000.00-0.630.800.00
Consolidated Net Income-91.09-104.99-105.32-132.49-128.18-83.89-66.33-34.10-15.71
Net Income From Continuing Operations-91.09-104.99-105.32-132.49-128.18-83.89-66.33-34.10-15.71
Net Income-91.09-104.99-105.32-132.49-128.18-83.89-66.33-42.57-24.11
EPS (Recurring)-0.67-1.18-1.49-2.66-2.62-1.82-1.45-0.99-0.57
EPS (Basic, Before Extraordinaries)-0.72-1.27-1.52-2.67-2.62-1.82-1.54-0.99-0.57
EPS (Diluted)-0.72-1.27-1.52-2.67-2.62-1.82-1.54-0.99-0.57
EBITDA-94.77-96.51-109.28-131.29-121.96-79.23-57.61-32.71-12.82
Non-Operating Income (Expense)10.9810.3514.439.813.580.390.392.160.68
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense11.8515.0923.4321.5230.0221.512.511.200.58
Price To Sales Ratio14.044.407.0213.519.2732.3842.98--
Gross Margin77.7477.8177.8262.7275.6593.65---
Operating Margin-315.86-290.68-329.30-669.84-416.56-179.39-182.10-165.81-84.64
Net Margin-282.22-292.08-295.96-638.34-412.19-183.23-199.83-199.09-124.49
Shares Outstanding131.3196.9170.6360.4748.9748.6943.0642.9942.09
Market Capitalization393.95393.95254.12278.44288.851,565.741,425.571,546.48-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue8.476.646.1511.0211.236.467.245.18
Cost of Goods Sold Incl. D&A1.791.791.801.812.072.082.011.77
Gross Profit6.684.854.359.219.164.385.223.41
Selling, General and Administrative Excl. Other31.2831.2732.1432.3532.8432.8834.3941.12
Research and Development24.8024.4724.6124.9825.9926.2027.0732.51
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-24.60-26.42-27.79-23.14-23.68-28.50-29.16-37.71
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.0010.730.000.000.00
Net Income Before Taxes-21.84-23.64-25.13-20.36-32.17-26.02-26.32-34.44
Income Taxes0.000.000.000.120.000.000.000.13
Consolidated Net Income-21.84-23.64-25.13-20.49-32.17-26.02-26.32-34.57
Net Income From Continuing Operations-21.84-23.64-25.13-20.49-32.17-26.02-26.32-34.57
Net Income-21.84-23.64-25.13-20.49-32.17-26.02-26.32-34.57
EPS (Recurring)-0.16-0.18-0.20-0.18-0.34-0.37-0.37-0.49
EPS (Basic, Before Extraordinaries)-0.16-0.18-0.20-0.18-0.44-0.37-0.37-0.49
EPS (Diluted)-0.16-0.18-0.20-0.18-0.44-0.37-0.37-0.49
EBITDA-22.81-24.63-25.98-21.34-21.61-26.42-27.15-35.94
Non-Operating Income (Expense)2.752.792.662.782.252.482.843.27
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.983.042.673.173.633.945.512.01
Price To Sales Ratio14.0417.429.516.215.352.972.857.14
Gross Margin78.9073.0570.7283.6181.5567.7572.1965.89
Operating Margin-290.46-397.88-451.64-210.10-210.85-440.99-402.93-728.39
Net Margin-257.95-355.90-408.47-185.97-286.43-402.60-363.66-667.82
Shares Outstanding131.31122.91104.0496.9174.1771.0170.9970.63
Market Capitalization393.95516.35256.63185.11158.00101.54113.58254.12

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments248.54244.90253.68276.15309.28371.6990.5536.31
Short Term Receivables2.403.1011.801.475.724.484.6286.44
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets7.179.765.719.9310.694.841.590.78
Total Current Assets258.11257.77271.19287.56325.69381.0196.77123.53
Net Property, Plant & Equipment45.2863.3871.0977.5235.0516.5518.9220.38
Total Investments and Advances52.0125.8031.4564.24145.482.582.582.58
Intangible Assets-----0.000.000.00
Deferred Tax Assets12.87-------
Other Assets3.682.652.721.530.540.000.000.00
Total Assets371.94349.60376.45430.84506.76400.14118.26146.49
Short Term Debt Incl. Current Port. of LT Debt6.375.775.226.991.331.040.880.73
Accounts Payable0.861.331.451.174.515.685.381.15
Other Current Liabilities25.8138.0836.1036.3945.4137.1327.3822.06
Total Current Liabilities33.0345.1842.7744.5551.2543.8533.6423.95
Long Term Debt53.6259.9865.7680.1741.5521.8812.8713.75
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Deferred Tax Liabilities12.87-------
Other Liabilities15.8428.4621.8116.8924.3753.6272.7277.55
Total Liabilities115.35133.62130.34141.61117.16119.35119.23115.25
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00111.00111.00
Common Equity256.59215.99246.11289.23389.61280.79-111.96-79.75
Total Shareholders Equity256.59215.99246.11289.23389.61280.79-0.9731.25
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity256.59215.99246.11289.23389.61280.79-0.9731.25
Total Liabilities & Stockholders Equity371.94349.60376.45430.84506.76400.14118.26146.49
Book Value Per Share2.653.064.075.918.006.52-2.60-1.89
Tangible Book Value Per Share2.653.064.075.918.006.52-2.60-1.89
Full-Time Employees104110145146121998888
Price to Book Ratio1.731.051.290.914.025.08-9.92-
Return on Assets-29.10-29.01-32.82-27.34-18.50-25.59-25.76-
Return on Equity-44.44-45.58-49.50-37.76-25.03-47.41-225.25-
Return on Invested Capital-33.85-38.16-42.48-34.70-19.46-21.92-286.52-34.92
Quick Ratio7.815.716.346.466.368.692.885.16
Current Ratio7.815.716.346.466.368.692.885.16

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-91.09-104.99-105.32-132.49-128.18-83.89-66.33-34.10-15.71
Depreciation7.248.398.248.047.572.912.842.743.57
Other Funds (Non Cash)10.1827.1924.2724.5531.4424.119.421.990.72
Funds from Operations-73.68-69.41-72.81-99.90-89.16-56.88-54.07-29.37-11.42
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-5.95-29.287.65-6.94-16.78-30.09-13.1884.98-5.56
Cash from Operating Activities-79.63-98.69-65.16-106.84-105.94-86.97-67.2555.61-16.98
Capital Expenditures-0.11-0.61-0.18-1.71-5.50-1.28-0.65-1.35-2.69
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.060.00
Purchase or Sale of Investments-99.86-7.99-51.09160.0663.92-188.06-189.85-0.3339.61
Purchase of Investments-313.34-227.07-284.32-129.90-219.53-537.74-293.86-79.00-4.99
Sale Or Maturity of Investments213.48219.08233.23289.95283.44349.68104.0078.6744.60
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-99.97-8.60-51.27158.3558.42-189.34-190.50-1.6236.92
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock152.99126.1244.9557.620.78171.51337.690.241.96
Repurchase of Common Pref Stock-0.25-0.19-0.19-0.110.000.00-0.19-0.03-0.06
Sale of Common Pref Stock153.24126.3245.1557.730.78171.51337.880.272.02
Proceedsfrom Stock Options152.24126.2144.3757.670.00169.18336.990.272.02
Issuance or Reduction of Debt, Net0.000.000.00-12.500.000.0011.970.000.00
Change in Long Term Debt0.000.000.00-12.500.000.0011.970.000.00
Issuance of Long Term Debt0.000.000.000.000.000.0011.970.000.00
Reduction of Long Term Debt0.000.000.00-12.500.000.000.000.000.00
Net Financing Active Other Cash Flow0.230.270.380.370.37-0.11-0.730.000.00
Other Financing Activities Uses0.000.000.000.000.00-0.11-0.730.000.00
Cash from Financing Activities153.22126.4045.3445.491.15171.40348.930.241.96
Net Change in Cash-26.3819.10-71.0997.00-46.37-104.9091.1854.2421.90
Free Cash Flow-79.74-99.30-65.34-108.55-111.44-88.24-67.9054.27-19.67
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00--
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments205.40253.66235.67248.54191.88214.55
Short Term Receivables1.411.332.882.406.542.16
Inventories0.000.000.000.000.000.00
Other Current Assets7.707.916.827.178.448.02
Total Current Assets214.50262.90245.37258.11206.86224.73
Net Property, Plant & Equipment40.0041.7943.5845.2847.0959.76
Total Investments and Advances72.7350.2336.0452.0111.3211.86
Deferred Tax Assets---12.87--
Other Assets4.574.493.873.680.210.18
Total Assets331.80359.40328.86371.94265.49296.53
Short Term Debt Incl. Current Port. of LT Debt6.846.686.526.376.226.07
Accounts Payable0.961.120.770.861.332.22
Other Current Liabilities33.6640.4519.9525.8128.4036.17
Total Current Liabilities41.4648.2527.2533.0335.9544.46
Long Term Debt48.4150.1851.9253.6255.2556.86
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---12.87--
Other Liabilities13.7713.7115.4415.8419.8921.15
Total Liabilities103.63112.1494.61115.35111.08122.46
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity228.17247.26234.25256.59154.41174.06
Total Shareholders Equity228.17247.26234.25256.59154.41174.06
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity228.17247.26234.25256.59154.41174.06
Total Liabilities & Stockholders Equity331.80359.40328.86371.94265.49296.53
Book Value Per Share1.742.012.252.652.082.45
Tangible Book Value Per Share1.742.012.252.652.082.45
Full-Time Employees---104--
Price to Book Ratio1.732.070.990.920.910.52
Return on Assets-30.50-30.92-32.02-29.10-37.12-32.93
Return on Equity-47.62-48.14-48.35-44.44-59.98-52.99
Return on Invested Capital-7.90-7.95-8.78-6.60-15.34-11.27
Quick Ratio5.175.459.007.815.765.06
Current Ratio5.175.459.007.815.765.06

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-21.84-23.64-25.13-20.49-32.17-26.02
Depreciation1.791.751.841.862.152.28
Other Funds (Non Cash)2.542.861.613.1714.844.43
Funds from Operations-17.51-19.03-21.67-15.46-15.18-19.30
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-8.4517.45-8.27-6.68-16.037.25
Cash from Operating Activities-25.97-1.57-29.94-22.14-31.21-12.06
Capital Expenditures0.00-0.04-0.06-0.01-0.41-0.18
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-20.58-14.7816.22-80.724.5039.11
Purchase of Investments-68.63-70.83-40.81-133.07-46.68-21.68
Sale Or Maturity of Investments48.0556.0557.0352.3551.1860.79
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-20.58-14.8116.15-80.734.0938.92
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.1933.730.41118.677.610.00
Repurchase of Common Pref Stock-0.040.00-0.20-0.01-0.020.00
Sale of Common Pref Stock0.2333.730.61118.697.630.00
Proceedsfrom Stock Options0.0033.550.00118.697.530.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.170.000.060.000.160.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.3633.730.46118.677.770.00
Net Change in Cash-46.1917.34-13.3315.79-19.3526.86
Free Cash Flow-25.97-1.61-30.01-22.16-31.62-12.24

Revenue breakdown

United States2024: 35.58M 2025: 35.95M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3038.58%46.6M120.8M2.42M
2026-10-1537.77%42.7M113.1M2.37M
2026-09-3035.71%40.4M113.1M2.54M
2026-09-1535.49%40.2M113.2M2.94M
2026-08-3133.40%37.4M112.0M3.02M
2026-08-1430.40%34.0M112.0M3.04M
2026-07-3130.00%30.4M101.4M3.25M
2026-07-1523.48%23.8M101.4M3.12M
2026-06-3024.64%25.0M101.4M3.22M
2026-06-1521.93%22.2M101.4M2.75M
2026-05-2921.60%21.7M100.2M2.96M
2026-05-1520.59%21.3M103.3M3.05M
2026-04-3025.68%21.1M82.0M2.59M
2026-04-1525.66%21.0M82.0M2.59M
2026-03-3119.78%16.2M81.7M2.09M
2026-03-1316.57%13.5M81.7M2.10M
2026-02-2710.43%8.5M81.7M1.76M
2026-02-138.78%7.1M81.1M1.50M
2026-01-309.19%7.2M78.4M1.64M
2026-01-159.41%7.4M78.4M1.78M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.001.702.450.0011.4930.000.000.963-0.0110.000
call2.000.601.601.106.72420.000.000.842-0.0240.001
call3.000.150.250.191.20326431.000.571-0.0160.002
call4.000.000.050.051.4982340.000.149-0.0090.001
call5.000.000.400.052.2503.000.000.111-0.0110.001
call6.000.000.750.052.8061.000.000.094-0.0120.001
put1.000.000.050.005.0980.000.00-0.037-0.0110.000
put2.000.000.200.103.7421880.00-0.158-0.0240.001
put3.000.000.300.171.6755440.00-0.435-0.0150.002
put4.000.601.350.713.36520.000.00-0.855-0.0090.001
put5.001.602.350.004.5440.000.00-0.890-0.0110.001
put6.002.503.500.006.0830.000.00-0.906-0.0120.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-09-258-KCurrent report2026-09-25SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-18SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-13144Filing for proposed sale of securities under Rule 144.SEC
2026-08-12144Filing for proposed sale of securities under Rule 144.SEC
2026-08-12SCHEDULE 13G/ASEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-07-27SCHEDULE 13GSEC
2026-07-134Statement of changes in beneficial ownership of securities2026-07-10SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-248-KCurrent report2026-06-24SEC
2026-06-118-KCurrent report2026-06-11SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010022.20K1
2025-120000
2025-110000

Institutional holders

Manager% owned
MORGAN STANLEY8.02%
RA CAPITAL MANAGEMENT, L.P.7.24%
BlackRock, Inc.7.14%
Lynx1 Capital Management LP6.63%
Squadron Capital Management LLC6.51%
Bain Capital Life Sciences Investors, LLC6.49%
JPMORGAN CHASE & CO4.29%
VANGUARD CAPITAL MANAGEMENT LLC4.00%
CITADEL ADVISORS LLC3.79%
WASATCH ADVISORS LP3.38%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.95%
iShares Russell 2000 ETF2.35%
Wasatch Ultra Growth Fund1.25%
Fidelity Small Cap Index Fund1.00%
VANGUARD EXTENDED MARKET INDEX FUND0.95%
iShares Russell 2000 Value ETF0.84%
Fidelity Enhanced Small Cap Core ETF0.71%
iShares Biotechnology ETF0.64%
Wasatch Micro Cap Fund0.62%
JNL Multi-Manager Small Cap Value Fund0.57%

OakChart. CCCC. Cached 15 minutes.